COMBI Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.08 |
| 52 Week High | SEK 4.30 |
| 52 Week Low | SEK 1.27 |
| Beta | 1.38 |
| 11 Month Change | -21.80% |
| 3 Month Change | -25.71% |
| 1 Year Change | -21.06% |
| 33 Year Change | -84.22% |
| 5 Year Change | -91.33% |
| Change since IPO | -98.84% |
Recent News & Updates
Shareholder Returns
| COMBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.3% | -3.4% | -1.4% |
| 1Y | -21.1% | 29.2% | 20.7% |
Return vs Industry: COMBI underperformed the Swedish Biotechs industry which returned 35% over the past year.
Return vs Market: COMBI underperformed the Swedish Market which returned 25.9% over the past year.
Price Volatility
| COMBI volatility | |
|---|---|
| COMBI Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: COMBI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: COMBI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 10 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
CombiGene AB (publ) Fundamentals Summary
| COMBI fundamental statistics | |
|---|---|
| Market cap | SEK 41.19m |
| Earnings (TTM) | -SEK 36.52m |
| Revenue (TTM) | SEK 4.29m |
9.6x
P/S Ratio-1.1x
P/E RatioIs COMBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COMBI income statement (TTM) | |
|---|---|
| Revenue | SEK 4.29m |
| Cost of Revenue | SEK 24.67m |
| Gross Profit | -SEK 20.38m |
| Other Expenses | SEK 16.15m |
| Earnings | -SEK 36.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -1.84 |
| Gross Margin | -474.52% |
| Net Profit Margin | -850.57% |
| Debt/Equity Ratio | 0% |
How did COMBI perform over the long term?
See historical performance and comparison